摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-chloro-6-(4-fluoro-2-methoxyphenyl)pyrimidine | 954221-72-8

中文名称
——
中文别名
——
英文名称
4-chloro-6-(4-fluoro-2-methoxyphenyl)pyrimidine
英文别名
——
4-chloro-6-(4-fluoro-2-methoxyphenyl)pyrimidine化学式
CAS
954221-72-8
化学式
C11H8ClFN2O
mdl
——
分子量
238.649
InChiKey
MCVYNDFDTIXNAI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.09
  • 拓扑面积:
    35
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • NOVEL 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES HAVING BOTH AROMATIC AND HALOGENIC SUBSTITUENTS
    申请人:Lori Franco
    公开号:US20140057911A1
    公开(公告)日:2014-02-27
    Certain 4,6-disubstituted aminopyrimidine derivatives having both aromatic and halogenic substituents.
    某些具有芳香族和卤素取代基的4,6-二取代氨基嘧啶衍生物。
  • [EN] N-(PYRIDIN-2-YL)PYRIMIDIN-4-AMINE DERIVATIVES CONTAINING A SULFOXIMINE GROUP<br/>[FR] DÉRIVÉS N-(PYRIDIN-2-YL)PYRIMIDIN-4-AMINES CONTENANT UN GROUPE SULFOXIMINE
    申请人:BAYER PHARMA AG
    公开号:WO2014076111A1
    公开(公告)日:2014-05-22
    The present invention relates to disubstituted N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfoximine group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/ or prophylaxis of disorders, in particular of hyper- proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    本发明涉及一种含有磺酰亚胺基团的二取代N-(吡啶-2-基)嘧啶-4-胺衍生物,其一般式(I)如所述和定义,并且涉及其制备方法,以及它们用于治疗和/或预防疾病,特别是增生性疾病和/或病毒感染性疾病和/或心血管疾病的方法。本发明还涉及用于制备所述一般式(I)化合物的中间体化合物。
  • 4, 6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES
    申请人:Wabnitz Philipp
    公开号:US20110306602A1
    公开(公告)日:2011-12-15
    The present invention relates to inhibitors of general Formula (I) of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to compounds for preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.
    本发明涉及一般公式(I)的细胞周期依赖性激酶抑制剂及其治疗应用。此外,本发明还涉及用于预防和/或治疗任何类型的疼痛、炎症性疾病、免疫性疾病、增殖性疾病、传染性疾病、心血管疾病和神经退行性疾病的化合物。
  • 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES
    申请人:Ingenium Pharmaceuticals GmbH
    公开号:US20130338147A1
    公开(公告)日:2013-12-19
    The present invention relates to inhibitors of cyclin-dependent kinases and therapeutic applications thereof. Furthermore, the invention relates to methods of preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases comprising the administration of an effective amount of at least one inhibitor of cyclin-dependent kinases.
    本发明涉及抑制细胞周期依赖性激酶及其治疗应用的药物。此外,本发明涉及通过给予至少一种细胞周期依赖性激酶抑制剂的有效剂量来预防和/或治疗任何类型的疼痛、炎症性疾病、免疫性疾病、增殖性疾病、传染性疾病、心血管疾病和神经退行性疾病的方法。
  • N-(PYRIDIN-2-YL)PYRIMIDIN-4-AMINE DERIVATIVES CONTAINING A SULFONE GROUP
    申请人:BAYER PHARMA AKTIENGESELLSCHAFT
    公开号:US20150274695A1
    公开(公告)日:2015-10-01
    The present invention relates to N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    本发明涉及含有磺酰基的N-(吡啶-2-基)嘧啶-4-胺衍生物的一般式(I),如本文所述和定义的方法及其制备方法,其用于治疗和/或预防疾病,特别是高增殖性疾病和/或病毒感染性疾病和/或心血管疾病。本发明还涉及在制备所述一般式(I)化合物中有用的中间体化合物。
查看更多